Pricing Log in Create free account

Kairos Pharma, Ltd. (KAPA) vs Karyopharm Therapeutics Inc. (KPTI)

Kairos Pharma, Ltd. and Karyopharm Therapeutics Inc. are both Biotechnology companies. Kairos Pharma, Ltd. is the larger, with a market value of $1.5M against $1.4M — 1.1× the size. Kairos Pharma, Ltd. has the higher net margin (0.00% vs −153.3%) and the lower return on invested capital (−322.9% vs 0.00%). Across the 12 metrics below, Kairos Pharma, Ltd. leads on 7 and Karyopharm Therapeutics Inc. on 5.

Valuation

Metric KAPA KPTI Biotechnology median
P/E n/m n/m 10.60
P/S n/m 0.01 9.40
P/B 0.36 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 0.21 n/m 0.66
EV/Sales n/m 1.27 9.02
Earnings yield (399.90%) (25,680.00%) (32.88%)
Free cash flow yield (264.69%) (4,526.16%) (23.13%)

Profitability

Metric KAPA KPTI Biotechnology median
Gross margin — 95.89% 68.51%
Operating margin 0.00% (56.17%) 0.00%
Net margin 0.00% (153.28%) 0.00%
Free cash flow margin 0.00% (44.57%) 0.00%
Return on equity (113.96%) 78.98% (51.96%)
Return on assets (104.32%) (207.90%) (46.06%)
Return on invested capital (322.91%) 0.00% 0.00%

Growth

Metric KAPA KPTI Biotechnology median
Revenue growth (TTM) — 6.81% 6.76%
EPS growth (last fiscal year) (30.44%) (28.07%) 29.88%
Revenue growth, 5-year CAGR — 6.21% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric KAPA KPTI Biotechnology median
Debt to equity 0.00 (0.76) 0.00
Current ratio 11.98 0.79 4.97
Net debt to EBITDA 1.65 (2.03) 1.01

Dividend

Metric KAPA KPTI Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric KAPA KPTI Biotechnology median
Market cap 1.54m 1.36m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack